Enzymes as Targets for Drug Design
eBook - PDF

Enzymes as Targets for Drug Design

  1. 267 pages
  2. English
  3. PDF
  4. Available on iOS & Android
eBook - PDF

Enzymes as Targets for Drug Design

About this book

Enzymes as Targets for Drug Design is a collection of scientific discussions related to enzyme inhibitors that show the many facets of the drug discovery process from the basic sciences through clinical applications. Topics include the biogenesis of phosphatidylinositol glycosyl membrane proteins, structure and catalytic function of ADP-ribose polymerase (ADPRT), and modulation of the dopaminergic system in cardiovascular therapeutics. The therapeutic utility of selected enzyme-activated irreversible inhibitors, the role of proteinases in the fibrosis of systemic sclerosis, and therapeutic opportunities in eicosanoid biosynthesis are also discussed.This book consists of 18 chapters and begins with examples of enzymes whose activities have recently been elucidated, or for which newer insights have been gleaned, but which do not yet have selective or potent inhibitors. The second part provides examples of enzymes where inhibitors have been identified but it is still not clear whether or not such an enzymatic blockade will be therapeutically beneficial. The final section describes clinical studies of newer, and not so new, enzyme inhibitors that are clearly of therapeutic importance. The therapeutic activity of monoamine oxidase inhibitors and the associated clinical issues are considered.This book is intended for clinicians as well as basic scientists in biochemistry, chemistry, pharmacology, and cell biology.

Frequently asked questions

Yes, you can cancel anytime from the Subscription tab in your account settings on the Perlego website. Your subscription will stay active until the end of your current billing period. Learn how to cancel your subscription.
No, books cannot be downloaded as external files, such as PDFs, for use outside of Perlego. However, you can download books within the Perlego app for offline reading on mobile or tablet. Learn more here.
Perlego offers two plans: Essential and Complete
  • Essential is ideal for learners and professionals who enjoy exploring a wide range of subjects. Access the Essential Library with 800,000+ trusted titles and best-sellers across business, personal growth, and the humanities. Includes unlimited reading time and Standard Read Aloud voice.
  • Complete: Perfect for advanced learners and researchers needing full, unrestricted access. Unlock 1.4M+ books across hundreds of subjects, including academic and specialized titles. The Complete Plan also includes advanced features like Premium Read Aloud and Research Assistant.
Both plans are available with monthly, semester, or annual billing cycles.
We are an online textbook subscription service, where you can get access to an entire online library for less than the price of a single book per month. With over 1 million books across 1000+ topics, we’ve got you covered! Learn more here.
Look out for the read-aloud symbol on your next book to see if you can listen to it. The read-aloud tool reads text aloud for you, highlighting the text as it is being read. You can pause it, speed it up and slow it down. Learn more here.
Yes! You can use the Perlego app on both iOS or Android devices to read anytime, anywhere — even offline. Perfect for commutes or when you’re on the go.
Please note we cannot support devices running on iOS 13 and Android 7 or earlier. Learn more about using the app.
Yes, you can access Enzymes as Targets for Drug Design by Michael Palfreyman in PDF and/or ePUB format, as well as other popular books in Medicine & Pharmacology. We have over one million books available in our catalogue for you to explore.

Information

Publisher
Academic Press
Year
2012
Print ISBN
9780125440301
eBook ISBN
9780323140485
Topic
Medicine
Subtopic
Pharmacology

Table of contents

  1. Front Cover
  2. Enzymes as Targets for Drug Design
  3. Copyright Page
  4. Table of Contents
  5. CONTRIBUTORS
  6. PREFACE
  7. ACKNOWLEDGMENTS
  8. CHAPTER 1. ENZYME INHIBITORS AS DRUGS
  9. CHAPTER 2. BIOGENESIS OF PHOSPHATIDYLINOSITOL GLYCOSYL MEMBRANE PROTEINS AND THEIR SIGNIFICANCE
  10. CHAPTER 3. STRUCTURE AND CATALYTIC FUNCTION OF ADP-RIBOSEPOLYMERASE (ADPRT), A TARGET SITE FOR DRUGS INHIBITING MALIGNANT GROWTH
  11. CHAPTER 4. MODULATION OF THE DOPAMINERGIC SYSTEM IN CARDIOVASCULAR THERAPEUTICS
  12. CHAPTER 5. ALPHA-METHYLDOPA
  13. CHAPTER 6. CONSIDERING RECEPTOR NON-SPECIFICITY AS A FACTOR FOR DEVELOPING EFFECT, TISSUE AND RECEPTOR SPECIFIC AGENTS1
  14. CHAPTER 7. MECHANISM-BASED ENZYME INHIBITORS AS AN APPROACH TO DRUG DESIGN
  15. CHAPTER 8. COFACTOR DEPENDENCY IN THE INHIBITION OF STEROID 5 ALPHA-REDUCTASE
  16. CHAPTER 9. HYDROXYLASES AS TARGETS FOR DRUG DESIGN
  17. CHAPTER 10. ALPHA-FLUOROMETHYLTYROSINE, ALPHA-FLUOROMETHYLTRYPTOPHAN AND BIOGENIC AMINE SYNTHESIS
  18. CHAPTER 11. TYROSINE AND TRYPTOPHAN ANALOGUES AS DUAL ENZYME-ACTIVATED INHIBITORS OF MONOAMINE OXIDASE
  19. CHAPTER 12. INHIBITION OF POLYAMINE BIOSYNTHESIS AND FUNCTION AS AN APPROACH TO DRUG DESIGN
  20. CHAPTER 13. CONCEPTS FOR DERIVING SPECIFIC INHIBITORS OF POLYAMINE BIOSYNTHESISHUMAN LUNG CANCER CELLS AS A MODEL SYSTEM
  21. CHAPTER 14. THERAPEUTIC UTILITY OF SELECTED ENZYME-ACTIVATED IRREVERSIBLE INHIBITORS
  22. CHAPTER 15. INTRA-BLOOD-BRAIN-BARRIER IgG SYNTHESIS IN HIV1
  23. CHAPTER 16. PROTEINASES IN THE FIBROSIS OF SYSTEMIC SCLEROSIS
  24. CHAPTER 17. THERAPEUTIC OPPORTUNITIES IN EICOSANOID BIOSYNTHESIS
  25. CHAPTER 18. MAO AS A TARGET FOR DRUG DESIGN: CLINICAL ISSUES
  26. Index